Vimek Bioconcept's TPHA kit for Syphilis screening receives CDSCO approval

New Delhi: Vimek Bioconcept, medical technology company's indigenous Treponema Pallidum haem-agglutination (TPHA) test kit for syphilis diagnosis has received approval from the Central Drugs Standard Control Organization (CDSCO) for distribution and sale within India.

TPHA test is known for its accuracy in diagnosing Syphilis, a sexually transmitted infection caused by the bacterium Treponema pallidum which requires timely and accurate diagnosis for effective treatment and prevention of its spread.

The Made in India TPHA kit will be one-twentieth the cost of a polymerase chain reaction (PCR) test empowering Indian blood banks, hospitals, and laboratories with a cost-effective and accurate solution for large-scale screening of Syphilis patients. The kit will be available from the month of August and will be distributed through their channel partners across India.

According to the company, the TPHA kit developed by Vimek has undergone rigorous testing and evaluation. The National Institute of Biologicals (NIB) has granted the kit approval with 100 per cent specificity and 100 per cent sensitivity.

Pratik Chitalia, Managing Director, Vimek Bioconcept, said, "This groundbreaking innovation bridges the gap between costly PCR-based tests which costs up to Rs. 600 and less accurate rapid tests, providing a semi-quantitative, affordable, and highly accurate screening option. Our mission is to make quality healthcare accessible to all, and this indigenous TPHA kit aligns perfectly with that vision and costs almost one-twentieth the cost of a PCR test."